Hypertension as an Independent Risk Factor for In-Patient Mortality in Hospitalized COVID-19 Patients : A Multicenter Study
Copyright © 2022, Mirza et al..
Despite the lack of direct evidence that hypertension increases the likelihood of new infections, hypertension is known to be the most common comorbid condition in COVID-19 patients and also a major risk factor for severe COVID-19 infection. The literature review suggests that data is heterogeneous in terms of the association of hypertension with mortality. Hence, it remains a topic of interest whether hypertension is associated with COVID-19 disease severity and mortality. Herein, we perform a multicenter retrospective analysis to study hypertension as an independent risk for in-hospital mortality in hospitalized COVID-19 patients. This multicenter retrospective analysis included 515 COVID-19 patients hospitalized from March 1, 2020 to May 31, 2020. Patients were divided into two groups: hypertensive and normotensive. Demographic characteristics and laboratory data were collected, and in-hospital mortality was calculated in both groups. The overall mortality of the study population was 25.3% (130 of 514 patients) with 96 (73.8%) being hypertensive and 34 (26.2%) being normotensive (p-value of 0.01, statistically non-significant association). The mortality rate among the hypertensive was higher as compared to non-hypertensive; however, hypertensive patients were more likely to be old and have underlying comorbidities including obesity, diabetes mellitus, coronary artery disease, congestive heart failure, stroke, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and cancer. Therefore, multivariable logistic regression failed to show any significant association between hypertension and COVID-19 mortality. To our knowledge, few studies have shown an association between hypertension and COVID-19 mortality after adjusting confounding variables. Our study provides further evidence that hypertension is not an independent risk factor for in-hospital mortality when adjusted for other comorbidities in hospitalized COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cureus - 14(2022), 7 vom: 15. Juli, Seite e26741 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mirza, Hasan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Covid-19 infection |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.26741 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343570130 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343570130 | ||
| 003 | DE-627 | ||
| 005 | 20231226020746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.26741 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343570130 | ||
| 035 | |a (NLM)35836713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mirza, Hasan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertension as an Independent Risk Factor for In-Patient Mortality in Hospitalized COVID-19 Patients |b A Multicenter Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Mirza et al. | ||
| 520 | |a Despite the lack of direct evidence that hypertension increases the likelihood of new infections, hypertension is known to be the most common comorbid condition in COVID-19 patients and also a major risk factor for severe COVID-19 infection. The literature review suggests that data is heterogeneous in terms of the association of hypertension with mortality. Hence, it remains a topic of interest whether hypertension is associated with COVID-19 disease severity and mortality. Herein, we perform a multicenter retrospective analysis to study hypertension as an independent risk for in-hospital mortality in hospitalized COVID-19 patients. This multicenter retrospective analysis included 515 COVID-19 patients hospitalized from March 1, 2020 to May 31, 2020. Patients were divided into two groups: hypertensive and normotensive. Demographic characteristics and laboratory data were collected, and in-hospital mortality was calculated in both groups. The overall mortality of the study population was 25.3% (130 of 514 patients) with 96 (73.8%) being hypertensive and 34 (26.2%) being normotensive (p-value of 0.01, statistically non-significant association). The mortality rate among the hypertensive was higher as compared to non-hypertensive; however, hypertensive patients were more likely to be old and have underlying comorbidities including obesity, diabetes mellitus, coronary artery disease, congestive heart failure, stroke, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and cancer. Therefore, multivariable logistic regression failed to show any significant association between hypertension and COVID-19 mortality. To our knowledge, few studies have shown an association between hypertension and COVID-19 mortality after adjusting confounding variables. Our study provides further evidence that hypertension is not an independent risk factor for in-hospital mortality when adjusted for other comorbidities in hospitalized COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a covid-19 infection | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a morbidity | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Noori, Muhammad Atif Masood |e verfasserin |4 aut | |
| 700 | 1 | |a Akbar, Hafsa |e verfasserin |4 aut | |
| 700 | 1 | |a Fichadiya, Hardik |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Ikwinder Preet |e verfasserin |4 aut | |
| 700 | 1 | |a Sachdeva, Sonali |e verfasserin |4 aut | |
| 700 | 1 | |a Grewal, Jagpreet |e verfasserin |4 aut | |
| 700 | 1 | |a Khakwani, Muhammad Zain |e verfasserin |4 aut | |
| 700 | 1 | |a Levitt, Howard |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Wang |e verfasserin |4 aut | |
| 700 | 1 | |a Wasty, Najam |e verfasserin |4 aut | |
| 700 | 1 | |a Patton, Chandler |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Angi, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Mughal, Mohsin S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 14(2022), 7 vom: 15. Juli, Seite e26741 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:7 |g day:15 |g month:07 |g pages:e26741 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.26741 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 7 |b 15 |c 07 |h e26741 | ||